Search Result

Results for "

manifestations

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (5) Amino Acid Derivatives (1) Endogenous Metabolite (1) GABA Receptor (2) Glycolate Oxidase (1) Imidazoline Receptor (5) Isotope-Labeled Compounds (1) Monoamine Oxidase (5) nAChR (2) NF-κB (1) Nuclear Factor of activated T Cells (NFAT) (1) Opioid Receptor (2) Reference Standards (1) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (4) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (7)
Oligonucleotides:	siRNA drugs (1) siRNAs (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132588

Lumasiran ALN-G01	Small Interfering RNA (siRNA) Glycolate Oxidase	Metabolic Disease
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) .

HY-59291

Levacetylleucine N-Acetyl-L-leucine	Amino Acid Derivatives	Neurological Disease Metabolic Disease Inflammation/Immunology
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .

HY-101392S

Harmane-d1	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Neurological Disease Cancer
Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively) .

HY-P1684

Peptide P60 FOXP3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a FOXP3 inhibitor. Peptide P60 can enter cells, inhibit the nuclear translocation of FOXP3, and diminish its ability to suppress the transcription factors NF-κB and NFAT. Peptide P60 can inhibit the immunosuppressive activity of regulatory T cells (Treg) derived from mice and humans, and enhance the stimulation of effector T cells in vitro. Peptide P60 can induce a lymphoproliferative autoimmune syndrome with pathological manifestations resembling those reported in scurfy mice lacking functional Foxp3. Peptide P60 can enhance the immunogenicity of cancer and viral vaccines.

HY-101392

Harmane 1 Publications Verification	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor	Neurological Disease Inflammation/Immunology
Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-127119

Benanserin hydrochloride	Endogenous Metabolite	Neurological Disease
Benanserin hydrochloride is a serotonin antagonist with psychopharmacological activity. Benanserin hydrochloride can be used to study specific behavioral manifestations in monitoring systems for drug effects. The effects of Benanserin hydrochloride can be sensitively and effectively assessed, for example, by measuring muscle movement capacity and reaction time. Benanserin hydrochloride is suitable for monitoring specific muscle physiological changes. The biological activity of Benanserin hydrochloride can provide reproducible bioassay parameters for experiments .

HY-101392S1

Harmane-d2	Isotope-Labeled Compounds Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Neurological Disease Cancer
Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively) .

HY-101392A

Harmane hydrochloride	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor	Neurological Disease Inflammation/Immunology
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-101392R

Harmane (Standard)	Reference Standards Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Neurological Disease Cancer
Harmane (Standard) is the analytical standard of Harmane. This product is intended for research and analytical applications. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect .

Cat. No.	Product Name

HY-L108

Antidepressant Compound Library	2,422 compounds
Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors. Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent. MCE offers a unique collection of 2,422 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

Antidepressant Compound Library

2,422 compounds

Depression is a serious global affective disorder and one of the most common neurological diseases whose clinical manifestations are low mood, loss of interest, anhedonia, loss of energy, and fatigue, people with major depressive disorder (MDD) can even have suicidal thoughts and behaviors.

Currently available antidepressants have significant limitations, including a long time lag for a therapeutic response (weeks to months) and low response rates. This is particularly problematic for a disease with a high suicide rate. Therefore, the development of new antidepressant drugs is particularly urgent.

MCE offers a unique collection of 2,422 compounds with antidepressant activities or targeting the unique targets of depression. MCE Antidepressant Compound Library is a useful tool for exploring the mechanism of depression and discovering new drugs for depression.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library	3,969 compounds
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 3,969 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,969 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,969 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

HY-L125

Anti-Pulmonary Fibrosis Compound Library	2,265 compounds
Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,265 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Anti-Pulmonary Fibrosis Compound Library

2,265 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,265 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P1684

Peptide P60 FOXP3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a FOXP3 inhibitor. Peptide P60 can enter cells, inhibit the nuclear translocation of FOXP3, and diminish its ability to suppress the transcription factors NF-κB and NFAT. Peptide P60 can inhibit the immunosuppressive activity of regulatory T cells (Treg) derived from mice and humans, and enhance the stimulation of effector T cells in vitro. Peptide P60 can induce a lymphoproliferative autoimmune syndrome with pathological manifestations resembling those reported in scurfy mice lacking functional Foxp3. Peptide P60 can enhance the immunogenicity of cancer and viral vaccines.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-59291

Levacetylleucine N-Acetyl-L-leucine	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Amino Acid Derivatives
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .

HY-101392

Harmane 1 Publications Verification	Alkaloids Structural Classification other families Source classification Pyridine Alkaloids Plants Indole Alkaloids	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-101392A

Harmane hydrochloride	Apocynaceae Structural Classification Alkaloids Other Alkaloids Source classification Plants Rauwolfia canescens	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor nAChR GABA Receptor Opioid Receptor
Harmane hydrochloride is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane hydrochloride inhibits the I1 imidazoline receptor (IC₅₀ = 30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane hydrochloride inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane hydrochloride can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-101392R

Harmane (Standard)	Structural Classification Alkaloids other families Source classification Plants	Reference Standards Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor
Harmane (Standard) is the analytical standard of Harmane. This product is intended for research and analytical applications. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect .

Cat. No.	Product Name	Chemical Structure

HY-101392S

Harmane-d1
Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively) .

Harmane-d1

Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively) .

HY-101392S1

Harmane-d2
Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively) .

Harmane-d2

Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for human MAO A/B, respectively) .

Cat. No.	Product Name		Classification